OX40 : Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Blood / Myeloma / Lymphoma,Breast,Head and neck,Lung,Skin,Stomach and upper gastrointestinal tract,Urinary systemBladder,Breast,Head and neck,Hodgkin's Disease (Hodgkin's Lymphoma),Liver,Lung,Melanoma (Skin),Merkel cell,Non-Small Cell Lung Cancer,Urothelial

Trial Overview Read MoreRead more

This phase I trial is evaluating a new targeted therapy alone and in combination with another type of targeted therapy to see if it is safe and tolerable for advanced cancer patients.
 

This trial is treating patients with advanced cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Commercial Sponsor

BeiGene Australia Pty Ltd

Summary

This is a dose escalation and expansion study. In the dose escalation phase (Phase Ia), eligible patients will receive intravenous BGB-A445 as a monotherapy in sequential cohorts of approximately 5 increasing dose levels on day 1 of each 21 day treatment cycle, OR receive BGB-A445 in combination with tislelizumab in sequential cohorts of approximately 3 increasing dose levels on day 1 of each 21 day treatment cycle. In the dose expansion phase (Phase Ib), eligible patients will receive a recommended Phase 2 does of intravenous BGB-A445 alone or in combination with tislelizumab as determined by the dose escalation phase.

Recruiting Hospitals Read MoreRead more

Monash Health, Medical Oncology
Clayton
Early Phase Research Study Coordinator
earlyphase.oncresearch@monashhealth.org
0474 769 510

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Enquiries Line Coordinator
clinicaltrials.enquiries@petermac.org
03 8559 7456 (9am-2pm, Mon-Fri)

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next